Show simple item record

AuthorShafei, L. K. I. A.
AuthorIbrahim, Mohamed Izham Mohamed
AuthorBilla, N.
Available date2022-04-10T10:25:30Z
Publication Date2021
Publication NameFrontiers in Pharmacology
ResourceScopus
URIhttp://hdl.handle.net/10576/29387
AbstractCurcumin, obtained from curcuma longa, has been the subject of decades of scientific investigation on its therapeutic usefulness. It is reported to possess several therapeutic properties, of which anti-colon cancer is of interest in this review. Clinically however, curcumin has yet to firm up its place among established anti-colon cancer therapeutic contenders. We aimed to systematically review prevailing clinical evidence on the role of curcumin in colon cancer treatment. The review drawing from literature on clinical studies indicates fairly long term tolerability. No regression of tumor was reported when curcumin was the sole intervention. Increase in p53 level expression was reported in a placebo controlled study but no reduction in PGE2 or 5HETE. Pharmacokinetic data on healthy humans indicate that formulated curcumin delivery systems present significantly higher systemic bioavailability. It appears therefore that the clinical use of curcumin can potentially be realized only through appropriate formulation interventions.
SponsorWe acknowledge Qatar University grant number QUST-2-CPH-2020-6 in supporting the research.
Languageen
PublisherFrontiers Media S.A.
Subjectcancer
clinical trial
colon
curcumin
formulation
nanoparticle delivery
outcome measures
systematic review
TitleIs Curcumin at the Threshold of Therapeutic Effectiveness on Patients with Colon Cancer?- A Systematic Review
TypeArticle Review
Volume Number12
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record